FLXN
Income statement / Annual
Last year (2020), Flexion Therapeutics, Inc.'s total revenue was $85.55 M,
an increase of 17.26% from the previous year.
In 2020, Flexion Therapeutics, Inc.'s net income was -$113.71 M.
See Flexion Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
| Operating Revenue |
$85.55 M
|
$72.96 M
|
$22.52 M
|
$355,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$19.25 M |
$9.96 M |
$7.34 M |
$4,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$66.30 M |
$63.00 M |
$15.19 M |
$351,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.78 |
0.86 |
0.67 |
0.99 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$54.33 M
|
$69.56 M
|
$53.08 M
|
$51.23 M
|
$41.31 M
|
$32.69 M
|
$17.92 M
|
$11.06 M
|
$11.07 M
|
$8.24 M
|
| General & Administrative
Expenses |
$105.00 M
|
$129.71 M
|
$121.31 M
|
$78.80 M
|
$28.47 M
|
$13.37 M
|
$9.06 M
|
$6.70 M
|
$3.95 M
|
$3.05 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$105.00 M
|
$129.71 M
|
$121.31 M
|
$78.80 M
|
$28.47 M
|
$13.37 M
|
$9.06 M
|
$6.70 M
|
$3.95 M
|
$3.05 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$159.32 M |
$199.27 M |
$174.39 M |
$130.03 M |
$69.78 M |
$46.06 M |
$26.99 M |
$17.77 M |
$15.01 M |
$11.29 M |
| Cost And Expenses |
$178.57 M |
$209.23 M |
$181.73 M |
$130.04 M |
$69.78 M |
$46.06 M |
$26.99 M |
$17.77 M |
$15.01 M |
$11.29 M |
| Interest Income |
$876,000.00 |
$3.21 M |
$4.57 M |
$3.72 M |
$1.52 M |
$1.25 M |
$478,715.00 |
$233,999.00 |
$193,900.00 |
$173,289.00 |
| Interest Expense |
$20.03 M |
$17.07 M |
$15.71 M |
$11.27 M |
$1.75 M |
$570,990.00 |
$401,370.00 |
$448,889.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$3.34 M
|
$2.40 M
|
$1.71 M
|
$2.01 M
|
$1.15 M
|
$238,153.00
|
$120,341.00
|
$79,808.00
|
$43,233.00
|
$105,574.00
|
| EBITDA |
-$89.84 M
|
-$130.31 M
|
-$152.23 M
|
-$124.21 M
|
-$69.00 M
|
-$45.51 M
|
-$26.79 M
|
-$17.66 M
|
-$14.94 M
|
-$11.34 M
|
| EBITDA Ratio |
-1.05 |
-1.79 |
-6.76 |
-349.87 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-1.09
|
-1.87
|
-7.07
|
-365.3
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$20.19 M
|
-$13.50 M
|
-$10.46 M
|
-$7.80 M
|
-$2.11 M
|
-$252,375.00
|
-$326,390.00
|
-$421,515.00
|
$30,023.00
|
-$159,375.00
|
| Income Before Tax |
-$113.21 M |
-$149.77 M |
-$169.66 M |
-$137.48 M |
-$71.89 M |
-$46.32 M |
-$27.31 M |
-$18.19 M |
-$14.98 M |
-$11.45 M |
| Income Before Tax Ratio
|
-1.32
|
-2.05
|
-7.53
|
-387.27
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$495,000.00 |
$3.56 M |
$5.26 M |
$3.47 M |
-$366,481.00 |
$318,615.00 |
$74,980.00 |
$27,374.00 |
$30,023.00 |
-$159,375.00 |
| Net Income |
-$113.71 M |
-$149.77 M |
-$169.66 M |
-$137.48 M |
-$71.89 M |
-$46.32 M |
-$27.31 M |
-$18.19 M |
-$14.98 M |
-$11.45 M |
| Net Income Ratio |
-1.33 |
-2.05 |
-7.53 |
-387.27 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.66 |
-3.93 |
-4.49 |
-4.16 |
-2.84 |
-2.15 |
-1.97 |
-1.23 |
-2.04 |
-1.18 |
| EPS Diluted |
-2.66 |
-3.93 |
-4.49 |
-4.16 |
-2.84 |
-2.15 |
-1.97 |
-1.23 |
-2.04 |
-1.18 |
| Weighted Average Shares
Out |
$42.78 M
|
$38.09 M
|
$37.75 M
|
$33.03 M
|
$25.30 M
|
$21.50 M
|
$13.89 M
|
$14.75 M
|
$7.34 M
|
$9.74 M
|
| Weighted Average Shares
Out Diluted |
$42.78 M
|
$38.09 M
|
$37.75 M
|
$33.03 M
|
$25.30 M
|
$21.50 M
|
$13.89 M
|
$14.75 M
|
$7.34 M
|
$9.74 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
